Biosimilars
This week we discuss what a biosimilar is, why they’re causing such controversy and why they’ve taken seven years, since the FDA approved Amgevita, to come to market. We review the evidence behind the safety and efficacy of these drugs, the data from switching from a bio-originator to a biosimilar, and how the approval of the drugs may lower the health care costs and improve access to these medications.
The podcast ACR on Air is embedded on this page from an open RSS feed. All files, descriptions, artwork and other metadata from the RSS-feed is the property of the podcast owner and not affiliated with or validated by Podplay.